CD33 and acute myeloid leukemia: Another study from Soldierer et al., revealed an optimal way of enriching CAR-NK cell isolates by using CD34 microbeads directed to the CD34 hinge on CAR-NK cells and subsequently evaluated both CD33- and CD123-based CARs in primary human NK cells, observing enhanced killing capacity against different AML cell lines and primary AML blasts in vitro [72].